Blog
Discover our latest articles and blogs
No Oral Tirzepatide in the U.S.: Get Clinician Led Care From $149
Oral tirzepatide is not FDA approved in the U.S. Learn why, which oral GLP1 options exist, and how to get clinician led care starting from $149.
5 Checks US Patients Must Do to Verify Compounded Semaglutide Safety
US-focused, actionable guidance on compounded semaglutide safety: five checks to verify your pharmacy and prescriber, plus FDA reports and clinician...
730+ Reports: Compounded Tirzepatide Safety for U.S. Patients
FDA records 730+ adverse reports and Lilly found impurities when tirzepatide mixed with B12. Learn U.S. safety steps and clinician supervised care.
1,000 mcg vs 2.4 mcg: GLP-1 Plus B12 Rarely Helps, FDA Concerns
Evidence-first look at GLP-1 plus B12: why a 1,000 mcg weekly dose rarely boosts weight loss, when B12 corrects deficiency, and FDA compounding risks.
No FDA Approval in 2026: Sublingual Tirzepatide and U.S. Pricing Data
2026 U.S. update: no FDA approval or large human trials for sublingual tirzepatide. We review preclinical sEV results, safety concerns, and U.S. pricing.
GLP-1 Coaching: 4 Pillars to Preserve Muscle and Keep Weight Off
Learn four clinician led coaching pillars that protect muscle and sustain weight loss on GLP-1 medication. Practical nutrition, strength, and taper plans.
0.8% Risk and Practical Steps for Semaglutide Patients With Hair Loss
Evidence-based summary for patients: semaglutide hair shedding is usually telogen effluvium from rapid weight loss. Reported rate ~0.8%. Tests, nutrition,...
LillyDirect $299–$449 vs Retail $1,079: U.S. Tirzepatide Costs, 2026
Updated U.S. tirzepatide pricing for 2026: retail pens near $1,079, LillyDirect $299–$449, and a Medicare Bridge option at $50. Find practical steps to...
Adults with Obesity: GLP‑1 Cuts AHI by 16.6 Events/Hour
Evidence-first brief for adults with obesity and moderate-to-severe OSA: reviews two 52-week trials, a pooled −16.6 AHI reduction, side effects, and...